We investigated the functional roles of ceramide, an intracellular lipid mediator, in cell signaling pathways by monitoring the intracellular movement of protein kinase C (PKC) subtypes fused to green fluorescent protein (GFP) in HeLa living cells. C 2 -ceramide but not C 2 -dihydroceramide induced translocation of ␦PKC-GFP to the Golgi complex, while ␣PKC-and PKC-GFP did not respond to ceramide. The Golgi-associated ␦PKC-GFP induced by ceramide was further translocated to the plasma membrane by phorbol ester treatment. Ceramide itself accumulated to the Golgi complex where ␦PKC was translocated by ceramide. Gamma interferon also induced the ␦PKC-specific translocation from the cytoplasm to the Golgi complex via the activation of Janus kinase and Mg 2؉ -dependent neutral sphingomyelinase. Photobleaching studies showed that ceramide does not evoke tight binding of ␦PKC-GFP to the Golgi complex but induces the continuous association and dissociation of ␦PKC with the Golgi complex. Ceramide inhibited the kinase activity of ␦PKC-GFP in the presence of phosphatidylserine and diolein in vitro, while the kinase activity of ␦PKC-GFP immunoprecipitated from ceramide-treated cells was increased. The immunoprecipitated ␦PKC-GFP was tyrosine phosphorylated after ceramide treatment. Tyrosine kinase inhibitor abolished the ceramide-induced activation and tyrosine phosphorylation of ␦PKC-GFP. These results suggested that gamma interferon stimulation followed by ceramide generation through Mg 2؉ -dependent sphingomyelinase induced ␦PKC-specific translocation to the Golgi complex and that translocation results in ␦PKC activation through tyrosine phosphorylation of the enzyme.
Protein kinase C (PKC) is a family of phospholipid-dependent serine/threonine protein kinases consisting of at least 10 subspecies that can be classified into three subgroups, classical, novel, and atypical PKC (43, 44, 52, 54) . The classical PKC members (␣, ␤I, ␤II, and ␥), each of which has a Ca 2ϩ binding region (C2 region) and two cysteine-rich regions, are activated by Ca 2ϩ , phosphatidylserine (PS), and diacylglycerol (DG) or phorbol esters. The novel PKC members (␦, ε, , and ), lacking the C2 region, are activated by PS and DG or phorbol esters without Ca 2ϩ . The atypical PKC members ( and /), which lack the C2 region and have only one cysteine-rich region, are dependent on PS but are not affected by DG, phorbol esters, or Ca 2ϩ (52) . Although a considerable number of studies have demonstrated the involvement of PKC in various cellular functions (2, 6, 42, 45, 62) , the individual roles of each PKC subtype in cellular functions remain unclear. Recent studies in living cells using green fluorescent protein (GFP)-tagged PKC have shown that each PKC subtype has a spatially and temporally different targeting mechanism that is dependent on the extracellular signals contributing to the subspeciesspecific functions of PKC (46, 49, 56, 59) . Based on these findings, it was proposed that the PKC targeting mechanism is a determinant for the specific function of each PKC subtype in response to various stimuli in various cell types.
Ceramide has recently emerged as an intracellular lipid mediator implicated in various cellular responses, such as programmed cell death, cell differentiation, growth inhibition, and long-term depression of synaptic transmission (5, 18, 19, 24, 47, 51, 64, 65) . Ceramide is generated by transient hydrolysis of sphingomyelin, and many reports have indicated that ceramide is produced via receptor-mediated stimulation by various extracellular ligands, including vitamin D 3 (50) , gamma interferon (IFN-␥) (25) , tumor necrosis factor alpha (TNF-␣) (11, 25) , interleukin-1 (36) , and nerve growth factor (5, 10) . Recently, the regulation of PKC activity by ceramide has been reported, but the results are still controversial; ceramide has been shown to activate ␣PKC or inhibit ␦PKC autophosphorylation in renal mesangial cells in vitro (22) . Furthermore, it is also reported that ceramide induces the translocation of ␦PKC and εPKC from the membrane to the cytosol in human myelogenous leukemia HL-60 cells (57) or of ␣PKC from the cytosol to the membrane in renal mesangial cells and in smooth muscle cells (22, 23) . These apparently contradictory results may have been due to differences not only in methods but also in time points and cell types examined, suggesting the necessity to observe the localization of each PKC subtype after ceramide treatment continuously in living cells.
In the present study, we investigated the intracellular movement of GFP-tagged PKC subtypes in living cells after treatment with various stimuli, such as ceramide and IFN-␥. We also examined the effect of ceramide on the kinase activity of PKC subtypes. We demonstrated here the ␦PKC-specific translocation to the Golgi complex by ceramide and the activation of ␦PKC through tyrosine phosphorylation of the enzyme.
MATERIALS AND METHODS
Materials. D-Erythro-C 2 -ceramide and D-erythrodihydro-C 2 -ceramide were purchased from Biomol Research Laboratories (Plymouth Meeting, Pa.).
D-Erythro-C 6 -ceramide and 6-{[N-(7-nitrobenz-2-oxa-1, 3-diazol-4-yl) amino] hexanoyl} sphingosine (C 6 -NBD-ceramide) were purchased from Molecular Probes (Eugene, Oreg.). 12-O-Tetradecanoylphorbol-13-acetate (TPA) was purchased from Sigma Chemical Co. (St. Louis, Mo.). D609 was purchased from Cayman Chemical (Ann Arbor, Mich.). IFN-␥ was a kind gift from Shionogi Research Laboratory and Co., Ltd. (Osaka, Japan). TNF-␣ was purchased from Gibco BRL (Grand Island, N.Y.). Scyphostatin was a kind gift from Takeshi Ogita (Biomedical Research Laboratories, Sankyo Co., Ltd., Tokyo, Japan). Glutathione (GSH) was purchased from Nacalai Tesque Inc. (Kyoto, Japan). Tyrphostin AG490 and genistein were purchased from Calbiochem-Novabiochem Co. (La Jolla, Calif.). Anti-␣PKC, ␦PKC, and εPKC monoclonal antibodies were purchased from Transduction Laboratories (Lexington, Ky.). Anti-␦PKC and PKC polyclonal antibodies were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, Calif.). Anti-PKC polyclonal antibody was purchased from Upstate Biotechnology (Lake Placid, N.Y.) and that used for immunoblotting was produced as described previously (53) . Anti-phosphotyrosine antibody, clone 4G10, was purchased from Upstate Biotechnology. Peroxidase-conjugated goat anti-mouse or anti-rabbit immunoglobulin G (IgG) was purchased from Amersham Corp. (Arlington Heights, Ill.). Cy3-labeled goat anti-mouse or anti-rabbit IgG was purchased from Amersham Corp. Calf thymus H1 histone was purchased from Boehringer GmbH (Mannheim, Germany). Myelin basic protein (MBP) was purchased from Sigma Chemical Co. Sodium fluoride (NaF) was purchased from Nacalai Tesque Inc. Sodium orthovanadate was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). All the other chemicals used were of analytical grade.
Cell culture. HeLa cells and HEK293 cells were purchased from Riken Cell Bank (Tsukuba, Japan). The CHO-K1 cell strain was a gift from Masahiro Nishijima (National Institute of Health, Tokyo, Japan). HeLa cells were cultured in minimum essential medium (Gibco BRL) which was buffered with 44 mM NaHCO 3 and supplemented with 10% fetal bovine serum (FBS) in 5% CO 2 at 37°C in a humidified incubator. HEK293 cells were maintained in minimum essential medium supplemented with 44 mM NaHCO 3 and 10% horse serum in a humidified atmosphere containing 5% CO 2 at 37°C. CHO-K1 cells were cultured as described previously (49, 59) . All media were supplemented with penicillin (100 U/ml) and streptomycin (100 g/ml), and the FBS used was not heat inactivated.
Preparation of ␦PKC-GFP adenovirus. The adenoviral plasmids (pAdEasy-1 and pAdEasy-2) and the shuttle vectors (pShuttle, pShuttle-CMV, pAdTrack, and pAdTrack-CMV) were gifts from Bert Vogelstein (Johns Hopkins University Oncology Center, Baltimore, Md.). Generation of an adenoviral vector including ␦PKC-GFP cDNA was performed according to the methods described on the web site of Johns Hopkins University Oncology Center (http://www.colon cancer.org/adeasy.html). Briefly, the plasmid encoding GFP (BS 348) was digested by BgIII and HindIII. The plasmid encoding ␦PKC (BS390) was digested with XhoI and BamHI, the digested products were subcloned into the XhoI and HindIII sites of the expression vector pShuttle-CMV, and the new plasmid was designated pBsAd010.
For the production of recombinant virus (␦PKC-GFP in pAdEasy-1), pBsAd010 linearized with PmeI was cotransformed with supercoiled circular pAdEasy-1 into competent Escherichia coli BJ5183 cells by electroporation. Transformation yielded approximately 10 kanamycin-resistant clones, of which about two-thirds contained recombinants, based on the sizes of undigested miniprep plasmid DNA. Candidate clones were digested with several restriction endonucleases to verify proper recombination. HEK293 cells at 50 to 70% confluency were prepared in 25-cm 2 flasks for transfection of adenoviral vector. Recombinant adenoviral vector DNA (ϳ4 g) including ␦PKC-GFP was digested with PacI and transfected into HEK293 cells by lipofection using TransIT-LT2 (Mirus, Madison, Wis.) according to the manufacturer's standard protocol. Transfected cells were monitored for GFP expression and were collected 7 to 10 days after transfection and then resuspended in 2 ml of phosphate-buffered saline without Ca 2ϩ or Mg 2ϩ [PBS(Ϫ)]. After three cycles of freezing in a methanol-dry ice bath and rapid thawing at 37°C, 500 l of viral lysate was used to infect 10 6 cells in 25-cm 2 flasks. Three or four days later, viruses were harvested as described above. To generate higher titer viral stocks, this process was repeated three times. In the final round, a total of 10 8 cells in 24 75-cm 2 flasks were used to obtain a multiplicity of infection of 5. Three to five days after the final infection, the resultant viruses were purified by CsCl banding, and final yields were measured as described previously (21) . Final yields were generally 10 11 to 10 12 PFU.
Expression of ␣PKC-, ␦PKC-, and PKC-GFP or ␦PKC protein in HeLa cells. GFP was fused to the C terminus of each PKC subtype. For lipofection, plasmids (ϳ5.5 g) including ␣PKC-, ␦PKC-, and PKC-GFP or ␦PKC cDNA were transfected into 5 ϫ 10 6 HeLa cells using TransIT-LT2 (Mirus) according to the manufacturer's standard protocol. For adenoviral infection, HeLa cells (5 ϫ 10 6 ) were incubated in serum-free medium for 2 h with recombinant ␦PKC-GFP adenovirus with a multiplicity of infection of 10 in a humidified atmosphere containing 5% CO 2 at 37°C. After infection, the viral supernatant was removed, and the cells were cultured in normal serum-containing medium. Adenoviral infection was performed in the immunoblotting experiments and kinase assays. The fluorescence of ␣PKC-, ␦PKC-, and PKC-GFP became detectable 16 h after transfection. All experiments were performed 2 days after transfection.
Observation of ␣PKC-, ␦PKC-, and -PKC-GFP translocation. HeLa cells expressing ␣PKC-, ␦PKC-, and PKC-GFP were spread onto glass-bottomed culture dishes (MatTek, Ashland, Mass.) and cultured for at least 16 h before observation. The culture medium was replaced with normal HEPES buffer composed of 135 mM NaCl, 5.4 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 , 5 mM HEPES, and 10 mM glucose, pH 7.3. The fluorescence of GFP was monitored under a confocal laser scanning fluorescence microscope (LSM 410 or 510; Carl Zeiss, Jena, Germany) at a 488-nm excitation wavelength with a 515-nm-long pass or 510-to 525-nm band pass barrier filter. Translocation of the fusion protein was triggered by addition of various stimulators at high concentrations into the HEPES buffer to obtain the appropriate final concentrations. All experiments were performed at 37°C.
Immunostaining of endogenous ␣PKC, ␦PKC, and PKC or expressed ␦PKC. Before and after treatment with 10 M C 2 -ceramide or C 6 -NBD-ceramide, HeLa cells were fixed with a fixative containing 4% paraformaldehyde and 0.2% picric acid in 0.01 M PBS (pH 7.4) for 30 min. After washing twice with PBS, the cells were treated with PBS containing 0.3% Triton X-100 and 5% normal goat serum (NGS) for 10 min. The cells were then incubated with the anti-␣PKC and -␦PKC monoclonal antibodies (diluted 1:200) or the anti-PKC polyclonal antibody (Upstate Biotechnology) (diluted 1:200) in PBS with 0.03% Triton X-100 (PBS-T) and 5% NGS for 1 h at 25°C. After washing in PBS-T, the cells were incubated with Cy3-labeled goat anti-mouse or anti-rabbit IgG (diluted 1:1,000) for 30 min. After three washes with PBS-T for 10 min each time, the fluorescence of Cy3 was observed under a confocal laser scanning fluorescent microscope with excitation at 588 nm using a 590-nm-long pass barrier filter.
Codetection of the Golgi complex and ␦PKC-GFP translocated by ceramide. Texas red-conjugated wheat germ agglutinin was used to monitor the Golgi complex. After translocation of ␦PKC-GFP by 10 M C 2 -ceramide, the cells were fixed with a fixative containing 4% paraformaldehyde and 0.2% picric acid in 0.01 M PBS (pH 7.4) for 30 min. After washing twice with PBS, the cells were treated with PBS containing 0.3% Triton X-100 and 5% NGS for 10 min. The cells were then incubated with 1 g of Texas red-conjugated wheat germ agglutinin (Molecular Probes, Leiden, The Netherlands) per ml for 40 min in PBS-T and 5% NGS. After three washes with PBS-T for 10 min each time, the fluorescence of Texas red and GFP was observed under a confocal laser scanning fluorescent microscope, with excitation at 488 nm using a 510-to 525-nm band pass barrier filter for the former and with excitation at 588 nm using a 590-nmlong pass barrier filter for the latter.
Cell fractionation and immunoprecipitation. For detection of endogenous PKC isozymes in HeLa cells, cultured HeLa cells were harvested with 1 ml of homogenate buffer (250 mM sucrose, 10 mM EGTA, 2 mM EDTA, 20 mM Tris-HCl, 200 g of leupeptin per ml, 1 mM phenylmethylsulfonyl fluoride, pH 7.4) and centrifuged at 2,000 ϫ g. For immunoblot analysis of tyrosine phosphorylation, we also used the homogenate buffer containing 10 mM NaF and 1 mM Na 3 VO 4 . The cells were resuspended with 300 l of homogenate buffer containing 1% Triton X-100 and sonicated (UD-210; Tomy Seiko Co. Ltd., Tokyo, Japan) (output, 5; duty, 50%) 10 times at 4°C, and the supernatant was used after centrifugation at 19,000 ϫ g for 15 min.
For subcellular fractionation, the HeLa cells transfected with the adenoviral vector containing ␦PKC-GFP were treated with 10 M C 2 -ceramide for 20 min at 37°C and then harvested with 1 ml of homogenate buffer and centrifuged at 2,000 ϫ g. The cells were resuspended with 300 l of homogenate buffer and sonicated as described above. The samples were centrifuged at 55,000 ϫ g for 30 min at 4°C, and the supernatant was collected as the cytosol fraction. The pellet was sonicated with 300 l of homogenate buffer containing 1% Triton X-100 and centrifuged at 19,000 ϫ g for 15 min, and then the supernatant was collected as the particulate fraction.
For immunoprecipitation of endogenous ␣PKC, ␦PKC, or PKC or expressed ␦PKC-GFP, the cytosol, particulate, or total fraction was rotated with the subtype-specific antibodies (anti-␣PKC, ␦PKC, or PKC) or anti-GFP polyclonal antibody (Molecular Probes) (diluted 1:50) for 2 h at 4°C and then with protein G-Sepharose for an additional 2 h. Samples were centrifuged at 2,000 ϫ g for 5 min at 4°C, and pellets were washed three times with PBS(Ϫ).
Finally, the pellet was suspended in 50 l of PBS(Ϫ) and used for phosphorylation or immunoblotting studies as described below.
Immunoblotting analysis. The same amounts of samples from each fraction were subjected to sodium dodecyl sulfate-7.5% polyacrylamide gel electrophoresis according to the method of Laemmli (28), and the separated proteins were electorophoretically transferred onto polyvinylidene difluoride (PVDF) filters (Millipore Co., Bedford, Mass.). Nonspecific binding sites on the PVDF filters were blocked by incubation with 5% nonfat milk or 2% bovine serum albumin in PBS-T for 18 h. The PVDF filters were then incubated with the anti-PKC monoclonal antibodies (␣PKC, ␦PKC, or εPKC) (diluted 1:1,000), the anti-PKC polyclonal antibodies (␦PKC, PKC, or PKC) (diluted 1:1,000), the anti-GFP polyclonal antibody (Clontech, Palo Alto, Calif.) (diluted 1:1,000), or anti-phosphotyrosine antibody (diluted 1:1,000) for 1 h at 25°C. After washing in PBS-T, the filters were incubated with peroxidase-conjugated goat anti-mouse or goat anti-rabbit IgG (diluted 1:10,000) for 30 min. After three rinses, the immunoreactive bands were visualized using an enhanced chemiluminescence detection kit (Amersham). After immunoblot using anti-phosphotyrosine antibody, the PVDF filter was washed according to the manufacturer's protocol for reprobing with anti-GFP polyclonal antibody.
Fluorescence photobleaching. Photobleaching experiments were performed as follows. After translocation of ␦PKC-GFP by 10 M C 2 -ceramide, a circular region in the Golgi complex or a square region of perikarya within a plane of the cell was photobleached by scanning for 15 s with an argon laser of the highest power. Recovery and fading of fluorescence in the selected regions were then analyzed by imaging the entire cell by confocal fluorescent microscopy with low laser power at the indicated times after photobleaching. For all of the images, the noise levels were reduced by line scan averaging.
In vitro and in vivo kinase assay of ␦PKC. The immunoprecipitated samples (10 l of suspended pellet) were used for both in vitro and in vivo kinase assays. In vitro kinase assays of ␦PKC-GFP expressed in HeLa cells were performed as described previously (49) . Briefly, the kinase activity in 10 l of each sample was assayed by measuring the incorporation of 32 P i into H1 histone from [␥-32 P]ATP in the presence of PS (8 g/ml), diolein (DO) (0.8 g/ml), or C 2 -ceramide at various concentrations. For the in vivo kinase assay, endogenous ␣PKC, ␦PKC, or PKC or exogenous ␦PKC-GFP was immunoprecipitated from HeLa cells at various time points after stimulation with 10 M C 2 -ceramide, and then the kinase activities were measured with H1 histone (␣PKC and ␦PKC) or MBP (PKC) as the substrate without any PKC activators such as PS, DO, or C 2 -ceramide.
RESULTS

Expression of PKC isozymes in HeLa cells.
The expression of endogenous PKC subtypes in HeLa cells was examined by immunoblotting using subtype-specific antibodies. In HeLa cell lysates, each antibody against ␣PKC, ␦PKC, or PKC detected an immunoreactive band of reasonable molecular weight, while ε and subtypes of PKC were not detected, indicating that the ␣, ␦, and subtypes of PKC are expressed in HeLa cells (Fig. 1) . In this study, therefore, we focused on the localization of ␣PKC, ␦PKC, and PKC but not of εPKC or PKC.
Translocation of ␣PKC, ␦PKC, and PKC induced by C 2 -ceramide and phorbol ester. When ␣PKC-and PKC-GFP were expressed in HeLa cells, intense and homogeneous fluorescence of ␣PKC-and PKC-GFP was observed throughout the cytoplasm, with no signals detected in the nucleus ( Fig. 2A  and C) . In contrast, faint but significant fluorescence of ␦PKC-GFP was seen in the nucleus in addition to intense fluorescence in the cytoplasm, and occasionally, ␦PKC-GFP was found more densely in the perinuclear region than in the surrounding cytoplasm ( Fig. 2A and C) . Localization of the fluorescence did not change for at least 60 min when observed under a confocal laser scanning fluorescence microscope without stimulation.
The effects of C 2 -ceramide, a membrane-permeable analogue of ceramide, on the cellular localization of ␣PKC-, ␦PKC, and PKC-GFP were investigated in HeLa cells. The ␦PKC-GFP accumulated significantly in the perinuclear region after treatment with C 2 -ceramide at 10 M. The intensity of fluorescence in the perinuclear region reached the maximum level at 20 min after treatment. The ␦PKC-GFP in the nucleoplasm was not altered by C 2 -ceramide. The fluorescence remained in the perinuclear region for at least 60 min after C 2 -ceramide treatment and did not return to the cytoplasm. On the other hand, application of 10 M C 2 -ceramide failed to induce any translocation of ␣PKC-or PKC-GFP ( Fig. 2A) . To verify the ␦PKC-specific translocation by ceramide, we further examined the effect of ceramide on endogenous ␣PKC, ␦PKC, and PKC in HeLa cells by immunocytochemistry. As shown in Fig. 2B , endogenous ␦PKC but not ␣PKC or PKC was significantly accumulated in the perinuclear region after the treatment, as seen in the case of ␦PKC-GFP. TPA at 1 M induced translocation of both ␣PKC-and ␦PKC-GFP but not of PKC-GFP from the cytoplasm to the plasma membrane within 15 min. Translocation from the nucleoplasm to the nuclear membrane was also observed only in the case of ␦PKC-GFP (Fig.  2C) . The fluorescence of ␣PKC-and ␦PKC-GFP remained on the plasma membrane or on the nuclear membrane for at least 60 min after TPA treatment.
C 2 -dihydroceramide, a derivative of C 2 -ceramide lacking the C 4 -C 5 double bond of the sphingoid backbone (4), did not induce significant translocation of ␦PKC-GFP (Fig. 3A) . C 2 -ceramide is known to be converted to C 2 -sphingomyelin by sphingomyelin synthase (SMS) (35, 55) . To determine whether C 2 -ceramide but not C 2 -sphingomyelin translocates ␦PKC-GFP, we studied the effects of D609, an inhibitor of SMS (35, 41, 58) , on the C 2 -ceramide-induced translocation of ␦PKC-GFP. Pretreatment with 200 g of D609/ml for 30 min failed to inhibit the C 2 -ceramide-induced translocation of ␦PKC-GFP (Fig. 3B ). After C 2 -ceramide-induced translocation of ␦PKC-GFP to the perinuclear region, TPA treatment (1 M, 3 min) induced translocation of both the perinuclear and cytosolic ␦PKC-GFP to the plasma membrane (Fig. 3C) . The ␦PKC-GFP in the nucleoplasm was translocated to the nuclear membrane 10 min after TPA treatment (data not shown).
Translocation of ␦PKC-GFP by ceramide was further examined by immunoblotting analysis. To determine whether ␦PKC-GFP was translocated from the cytosol to the particu- 1) were separated by sodium dodecyl sulfate-7.5% polyacrylamide gel electrophoresis, transferred onto nitrocellulose membranes, and stained with antibodies against each PKC subtype. Rat brain homogenate was used as a positive control for ␣PKC, ␦PKC, εPKC, and PKC, and recombinant PKC expressed in CHO-K1 cells was used as a positive control for PKC (lanes 2). The ␣, ␦, and subtypes of PKC were detected with reasonable molecular masses in HeLa cells. The results shown are representative of two independent experiments. VOL. 21, 2001 CERAMIDE AND PKC TRANSLOCATIONlate fraction by C 2 -ceramide, immunoblotting analysis was performed. ␦PKC-GFP was immunoprecipitated from the transfected HeLa cells using anti-N terminus of ␦PKC monoclonal antibody and stained with anti-C terminus of ␦PKC polyclonal antibody as described in Materials and Methods. As shown in Fig. 4 (left panel), ␦PKC-GFP was predominantly present in the cytosolic fraction before C 2 -ceramide treatment, and C 2 -ceramide (10 M, 20 min) caused translocation of ␦PKC-GFP from the cytosol to the particulate fraction. In addition, we obtained the same results using anti-GFP antibody instead of anti-N terminus of ␦PKC antibody for immunoprecipitation (data not shown). These results suggested that no degradation of ␦PKC-GFP occurred in the nontreated cells or even in the cells treated with C 2 -ceramide. We further examined whether the total amounts of ␦PKC-GFP were altered during C 2 -ceramide treatment by immunoblot analysis using anti-␦PKC monoclonal antibody. The amount of ␦PKC-GFP in the total homogenate of transfected HeLa cells was not altered by C 2 -ceramide treatment (Fig. 4, right panel) . Intracellular movement of ceramide. To compare the time course of ␦PKC-GFP translocation with permeation of ceramide into cells, we monitored the movement of ceramide in HeLa cells using a fluorescent analogue of ceramide, C 6 -NBDceramide. After application of 10 M C 6 -NBD-ceramide to HeLa cells, the fluorescence of C 6 -NBD-ceramide was first detected on the plasma membrane at 1 min, and weak signals were in the perinuclear region, and then the intensity of the fluorescence on the plasma membrane gradually increased until 10 min. Obvious accumulation of the fluorescence was seen in the perinuclear region at 3 min, and the intensity of fluorescence was markedly increased at 10 min (Fig. 5A, top row) . The C 6 -NBD-ceramide accumulated at the perinuclear region was not altered by TPA treatment (1 M, 15 min) (data not shown). C 6 -ceramide also induced the translocation of ␦PKC-GFP similarly to the effect of C 2 -ceramide. The accumulation of ␦PKC-GFP was first seen at 1 min and was apparent 3 min after treatment with C 6 -ceramide, and the intensity of GFP fluorescence in the perinuclear region increased until 10 min (Fig. 5A, bottom row) and reached a maximum at 20 min (data not shown).
To identify whether C 6 -ceramide translocates ␦PKC-GFP to the same intracellular compartment that C 6 -NBD-ceramide accumulates in, the ␦PKC was visualized with anti-␦PKC monoclonal antibody in HeLa cells overexpressing ␦PKC after C 6 -NBD-ceramide treatment. As shown in Fig. 5B , intense NBD fluorescence was present in the perinuclear region. ␦PKC immunoreactivity also accumulated in the perinuclear region. Merged images showed that the fluorescence of NBD and ␦PKC immunoreactivity were colocalized in the perinuclear region, indicating that C 6 -NBD-ceramide and ␦PKC are targeted to the same perinuclear compartment.
Translocation of ␦PKC-GFP induced by IFN-␥. The effect of IFN-␥, which hydrolyzes sphingomyelin to generate ceramide, on the translocation of ␦PKC-GFP was investigated in HeLa cells, since these cells are known to express IFN-␥ receptors (33). IFN-␥ at 100 U/ml induced significant ␦PKC- GFP translocation from the cytoplasm to the perinuclear region within 5 min, and the intensity of fluorescence increased in the perinuclear region until 30 min (Fig. 6A, top row) . We examined the influence of serum deprivation on the translocation of ␦PKC-GFP induced by IFN-␥. When the culture medium was replaced with serum-free medium, IFN-␥ induced the same translocation of ␦PKC-GFP as seen in the presence of FBS (Fig. 6A, bottom row) . Serum deprivation did not alter the localization of ␦PKC-GFP until at least 60 min after treatment (data not shown). The application of 100 U of IFN-␥ per ml failed to induce ␣PKC-or PKC-GFP translocation for at least 60 min (Fig. 6B and C) .
We further examined the downstream signaling pathway after activation of the IFN-␥ receptor, which contributes to the translocation of ␦PKC. IFN-␥ has been known to cause the activation of sphingomyelinase and then produce ceramide from sphingomyelin (25) . To determine whether the IFN-␥-induced translocation of ␦PKC-GFP is mediated by the activation of sphingomyelinase, we first examined the effect of the Mg 2ϩ chelator EDTA, which inhibits Mg 2ϩ -dependent neutral sphingomyelinase, a subtype of sphingomyelinase (5, 14) . As shown in Fig. 7A , pretreatment with Mg 2ϩ -free HEPES buffer containing 0.5 mM EDTA for 30 min entirely blocked the IFN-␥-induced translocation of ␦PKC-GFP (Fig. 7A, top row) , while in normal HEPES buffer IFN-␥ induced translocation of ␦PKC-GFP from the cytoplasm to the perinuclear region (Fig.  7A, bottom row) . The effects of other inhibitors of Mg 2ϩ -dependent neutral sphingomyelinase (scyphostatin and GSH) (3, 34, 63) were further examined. Pretreatment with 50 M scyphostatin for 15 min effectively blocked the translocation of 
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CERAMIDE AND PKC TRANSLOCATION␦PKC-GFP induced by IFN-␥, and the further application of 10 M C 2 -ceramide also rescued the perinuclear translocation of ␦PKC-GFP (Fig. 7B, top row) . Similarly, pretreatment with 5 mM GSH for 30 min effectively inhibited the translocation of ␦PKC-GFP induced by IFN-␥, and the further application of 10 M C 2 -ceramide rescued the perinuclear translocation of ␦PKC-GFP fluorescence (Fig. 7B, bottom row) . Tyrosine kinases such as JAK1 and JAK2 are involved in the downstream stages of IFN-␥ signaling pathways (40) . To clarify whether the perinuclear translocation of ␦PKC-GFP induced by IFN-␥ is mediated by the activation of JAK1 and JAK2 in HeLa cells, we investigated the effects of genistein or tyrphostin AG490 on the IFN-␥-induced translocation of ␦PKC-GFP. Pretreatment with 100 M genistein, a nonspecific tyrosine kinase inhibitor, for 30 min effectively blocked the translocation of ␦PKC-GFP induced by IFN-␥, and further application of 10 M C 2 -ceramide rescued the perinuclear translocation of ␦PKC-GFP (Fig. 8, top row) . Pretreatment with 100 M tyrphostin AG490, a specific inhibitor of JAK2 tyrosine kinase (1, 37, 66), for 30 min also blocked the translocation of ␦PKC-GFP induced by IFN-␥, and the further application of 10 M C 2 -ceramide rescued the perinuclear translocation of ␦PKC-GFP fluorescence as seen in the case of treatment with sphingomyelinase inhibitors (Fig. 8, bottom row) . Ceramide is also generated by the activation of TNF-␣ receptors, which are expressed in HeLa cells (11, 13, 25, 38) . We studied the effects of TNF-␣ on the translocation of ␦PKC-GFP. TNF-␣ at 100 U/ml induced apparent ␦PKC-GFP translocation from the cytoplasm to the perinuclear region within 20 min, and the intensity of the fluorescence increased slowly in the perinuclear region until 60 min (data not shown).
Target site of ␦PKC-GFP in response to ceramide. To identify the intracellular compartment where ␦PKC-GFP accumulated in response to C 2 -ceramide, the Golgi complex was visualized with Texas red-conjugated wheat germ agglutinin in HeLa cells expressing ␦PKC-GFP after ceramide treatment. As shown in Fig. 9 , intense GFP fluorescence was present in the perinuclear region in addition to moderate fluorescence throughout the cytoplasm. Texas red fluorescence accumulated in the perinuclear region and was also seen on the nuclear membrane. Merged images showed that the fluorescence of GFP and that of Texas red were colocalized in the perinuclear region, indicating that ␦PKC-GFP is targeted to the Golgi complex in response to ceramide. Colocalization of ␦PKC-GFP and Texas red-conjugated wheat germ agglutinin was also seen after stimulation with C 6 -ceramide or IFN-␥ (data not shown).
FRAP of ␦PKC-GFP translocated by ceramide. We investigated the interaction of ␦PKC-GFP with the Golgi complex by fluorescence recovery after photobleaching (FRAP). We measured the fluorescence recovery of the ␦PKC-GFP in the bleached area and also the fluorescence fading in the unbleached area after photobleaching with an argon laser at 488 nm. As shown in Fig. 10 , after treatment with 10 M C 2 -ceramide for 30 min, photobleaching of a circular area in the Golgi complex abolished the fluorescence of ␦PKC-GFP in the circle. The GFP fluorescence in the circle recovered within 40 s to a level similar to that in the unbleached Golgi complex. The recovery of fluorescence was significantly faster than the translocation of ␦PKC-GFP induced by ceramide (Fig. 5A ). In contrast, the fluorescence in the unbleached perikarya faded gradually. Photobleaching was also applied to a square area in perikarya (Fig. 10) . GFP fluorescence of the bleached area (perikarya) rapidly recovered (within 30 s), and the fluorescence in the Golgi complex rapidly faded.
Changes in kinase activity of ␦PKC by C 2 -ceramide, in vitro and in vivo. The effects of C 2 -ceramide on the kinase activity of ␦PKC-GFP were examined by an in vitro kinase assay. As shown in Fig. 11A , C 2 -ceramide at 10 M failed to activate ␦PKC-GFP in vitro. In the presence of PS and DO, the kinase activity of ␦PKC-GFP was increased 2.9-fold, and C 2 -ceramide inhibited the activation of ␦PKC-GFP by PS and DO. The activity of ␦PKC-GFP in the presence of the cofactors was dose-dependently inhibited by C 2 -ceramide, and the maximal level was seen at 10 M (31% inhibition).
In contrast, the in vivo kinase assay indicated that the kinase activity of the immunoprecipitated ␦PKC-GFP was increased in HeLa cells treated with C 2 -ceramide. Treatment with 10 M C 2 -ceramide increased the kinase activity of the immunoprecipitated ␦PKC-GFP in a time-dependent manner, and at 20 min after treatment with C 2 -ceramide, the kinase activity was increased 1.7-fold (Fig. 11B) . To examine whether endogenous ␦PKC is also activated by ceramide, we performed the in vivo kinase assay of endogenous ␣PKC, ␦PKC, and PKC in untransfected HeLa cells. After the treatment with 10 M C 2 -ceramide for 20 min, the kinase activity of ␦PKC but not of ␣PKC or PKC was significantly increased 1.6-fold (Fig. 11C) .
Tyrosine phosphorylation of ␦PKC-GFP after treatment with C 2 -ceramide in HeLa cells. It has been reported that ␦PKC is activated by tyrosine phosphorylation after various stimulations (8, 9, 17, 27, 30, 31, 60) . To elucidate whether or not the ceramide-induced activation of ␦PKC-GFP is through tyrosine phosphorylation, we investigated the effect of tyrosine kinase inhibitor on the C 2 -ceramide-induced activation of ␦PKC-GFP. Treatment with 10 M C 2 -ceramide induced significant activation of ␦PKC-GFP, while treatment with 10 M C 2 -dihydroceramide for 20 min did not induce significant activation of ␦PKC-GFP (Fig. 12A) . The activation of ␦PKC-GFP by C 2 -ceramide was abolished by the pretreatment with 200 M genistein, a nonspecific tyrosine kinase inhibitor (Fig.  12A ). To determine whether or not ␦PKC-GFP was tyrosine phosphorylated after the treatment with C 2 -ceramide, tyrosine phosphorylation of ␦PKC-GFP was analyzed by immunoblotting using an anti-phosphotyrosine antibody. Although C 2 -dihydroceramide did not cause any tyrosine phosphorylation of ␦PKC-GFP, ␦PKC-GFP was significantly tyrosine phosphorylated by treatment with C 2 -ceramide (Fig. 12B) . In addition, pretreatment with 200 M genistein effectively blocked the tyrosine phosphorylation of ␦PKC-GFP induced by C 2 -ceramide. Immunoblotting with the anti-GFP antibody revealed that similar amounts of ␦PKC-GFP were immunoprecipitated in all samples.
DISCUSSION
We have studied the targeting mechanism of PKC subtypes in living cells using GFP fusion proteins to elucidate the individual function of each PKC subtype. In CHO-K1 cells overexpressing ␥PKC-, ␦PKC-, and εPKC-GFP, spatial and temporal targeting varied depending on PKC subtype and extracellular stimulus (49, 56, 59) . We further demonstrated that PKC translocation to the specific intracellular compartment (PKC targeting) is necessary for the recognition and phosphorylation of the substrates in the compartment (48) . This subtype-and stimulus-specific targeting strongly suggested that the targeting mechanisms of PKC subtypes determine their individual roles in cell signaling pathways. In the present study, we examined the effects of ceramide on PKC translocation to clarify how ceramide is involved in various cell responses, especially in PKC-mediated signaling pathways.
Since HeLa cells express IFN-␥ receptors coupled to the sphingomyelin-ceramide pathway, we used HeLa cells that en- dogenously express ␣PKC, ␦PKC, and PKC for the present study. Among these three endogenously expressed PKC subtypes, only ␦PKC was translocated to the Golgi complex by a permeable ceramide analogue. Immunoblotting analysis indicated that ceramide induced translocation of ␦PKC from the cytosol to the particulate fraction, suggesting that ␦PKC was associated with the Golgi membrane after ceramide treatment. Immunocytochemical studies also revealed that ceramide translocated endogenous ␦PKC but not ␣PKC or PKC to the Golgi complex. The results of the present study in living cells suggested that only ␦PKC, at least in HeLa cells, is responsible for the ceramide-induced cellular responses, although it is possible that other PKC subtypes expressed at undetectable levels in HeLa cells are also involved in the responses or that ceramide acts on PKC without translocation of PKC to specific subcellular compartments. Shirai et al. demonstrated that among ␥PKC, ␦PKC, and εPKC, only ␦PKC was insensitive to various fatty acids, including arachidonic acid, which induced translocation of εPKC to the Golgi complex (59) . Ceramide also translocated εPKC but not ␥PKC to the Golgi complex in the present study (data not shown). Since ceramide translocates both εPKC and ␦PKC to the Golgi complex and arachidonic acid translocates only εPKC but not ␦PKC, it is suggested that arachidonic acid-induced translocation of εPKC to the Golgi complex may occur by a mechanism different from that involved in ceramide-induced translocation of ␦PKC and εPKC to the Golgi complex. Previous biochemical studies, however, showed that ␣PKC and ␦PKC have ceramide-binding abilities and that treatment with ceramide translocated εPKC as well as ␦PKC from the membrane to the cytosol fraction (57) . It was also reported that ceramide induced translocation of ␣PKC from the cytosol to the membrane fraction (22) and that PKC was translocated to the perinuclear region by ceramide (16) . In the present study using living HeLa cells, neither ␣PKC nor PKC responded to ceramide 60 min after treatment. The precise reason for this discrepancy is not clear, but it may have been due to differences in the cell types or experimental conditions used.
Many studies have shown that ceramide is produced through sphingomyelin hydrolysis after exposure to various extracellular stimuli, including IFN-␥ (25) and TNF-␣ (11, 25) . As shown in Fig. 6 downstream of the Mg 2ϩ -dependent neutral sphingomyelinase pathway. Furthermore, the chelation of extracellular Mg 2ϩ completely blocked the translocation of ␦PKC, demonstrating that the Mg 2ϩ -dependent neutral sphingomyelinase is activated outside the plasma membrane. Since D609, an inhibitor of SMS, did not alter the ceramide-induced translocation of ␦PKC or that induced by IFN-␥, ceramide generated by hydrolysis of sphingomyelin, but not sphingomyelin generated from ceramide, induced PKC translocation. Although serum deprivation has been reported to induce sphingomyelin hydrolysis and generation of ceramide within 10 h after treatment (24) , the serum deprivation did not alter localization of ␦PKC, at least within the 60-min observation period in the present study. Furthermore, because IFN-␥ induced translocation both in the presence and absence of serum, translocation of ␦PKC did not occur through an unknown effect of serum. The TNF-␣ receptor is also known to be expressed in HeLa cells (13, 38) , and TNF-␣ also induced similar but slower translocation of ␦PKC (data not shown). From the present findings that both AG490, a JAK2 inhibitor, and genistein, a tyrosine kinase inhibitor, completely blocked IFN-␥-induced translocation of ␦PKC, it is likely that Mg 2ϩ -dependent neutral sphingomyelinase is activated downstream of the IFN-␥ receptor-JAK pathway and that ceramide is subsequently produced, leading to translocation of ␦PKC to the Golgi complex, although the detailed pathway between JAK2 and Mg 2ϩ -dependent sphingomyelinase is currently unclear.
Ceramide is widely used as a marker for the Golgi complex, as ceramide accumulates in this organelle (32) . As shown in Fig. 5 , C 6 -NBD-ceramide accumulated to the perinuclear region with a time course similar to that of C 6 -ceramide-induced translocation of ␦PKC, and finally, ceramide and ␦PKC accumulated to the same compartment, the Golgi complex (Fig.  5B ). This simultaneous translocation of ␦PKC with ceramide to the Golgi complex suggested that the translocation of ␦PKC was due to its association with ceramide accumulating in the Golgi complex. However, NBD-ceramide was transiently accumulated on the plasma membrane just after application, but ceramide treatment did not cause translocation of ␦PKC to the plasma membrane. These observations suggested that ceramide may act on ␦PKC only at the Golgi complex but not at the plasma membrane. Although it is unclear whether ␦PKC binds ceramide directly or indirectly, it is possible that other components, such as anchoring protein, are necessary for the association of ␦PKC with ceramide in the Golgi complex. While the Golgi-associated ␦PKC following ceramide treatment was further translocated to the plasma membrane by TPA, the Golgi-associated NBD-ceramide was not altered by TPA treatment. This strongly suggested that the binding of ␦PKC to the Golgi complex is reversible and that the association and dissociation of ␦PKC with the Golgi complex occurred continuously. Rapid recovery of fluorescence into the bleached areas and fading of the fluorescence in the unbleached areas ( Fig. 10) suggested that ␦PKC does not bind tightly to the Golgi complex but continuously moves in both directions between the Golgi complex and the cytoplasm.
The effects of ceramide on PKC activity are controversial; ceramide has been reported to inhibit ␣PKC activity by an indirect mechanism (29) and to have no direct effect on PKC activity (20) , while Huwiler et al. reported an inhibitory effect of ceramide on ␦PKC activity in the presence of PKC activators such as DG and PS (22) in vitro. We found that ceramide did not affect the basal activity of ␦PKC but dose-dependently inhibited the kinase activity in the presence of PS and DO in vitro. It is noteworthy, however, that the activity of the immunoprecipitated ␦PKC was increased after ceramide treatment in vivo (Fig. 11B ). An increase in kinase activity of immunoprecipitated ␦PKC was also seen after treatment with IFN-␥ (1.6-fold increase) but not with dihydroceramide (data not shown). These results suggested that ␦PKC is not activated by a direct interaction with ceramide but is activated by unknown factors that are modulated by ceramide in the Golgi complex. Tyrosine phosphorylation is a candidate to explain the unknown factor activating ␦PKC in the Golgi complex. There is increasing evidence that ␦PKC is activated by its tyrosine phos- phorylation after various stimulations of the cells (8, 9, 17, 27, 30, 31, 60) . To elucidate the involvement of tyrosine phosphorylation in ceramide-induced activation of ␦PKC, we examined the effect of a tyrosine kinase inhibitor on ceramide-induced activation of ␦PKC and also on the ceramide-induced tyrosine phosphorylation of ␦PKC. As shown in Fig. 12 , ceramide induced tyrosine phosphorylation of ␦PKC as well as the activation of ␦PKC, and genistein, a tyrosine kinase inibitor, abolished both tyrosine phosphorylation and activation of ␦PKC. Considering that genistein did not block the ceramide-induced translocation of the ␦PKC (Fig. 8) , tyrosine phosphorylation of ␦PKC is not necessary for the translocation of ␦PKC to the Golgi complex. Currently, the tyrosine kinase which phosphorylates ␦PKC in response to ceramide remains unclear. These results strongly suggest that ceramide induces the ␦PKC-specific translocation to the Golgi complex and also induces the ␦PKC-specific activation by tyrosine phosphorylation in the Golgi complex.
Ceramide, one of the most important second messengers, has been shown to regulate various biological processes (19, 24, 47, 51, 64, 65) . Among these multiple functions, ceramide has attracted attention as an intracellular mediator of apoptosis. C 2 -ceramide as well as ceramide generation after treatment with TNF-␣ caused DNA fragmentation (15, 47) . Furthermore, Chin et al. reported that IFN-␥ also induced apoptosis through the STAT signaling pathway (7) . The involvement of ␦PKC in apoptosis in various types of cells was demonstrated after exposure to various extracellular stimuli (12, 26, 39, 61) . These reports strongly suggested that ceramide-induced translocation of ␦PKC to the Golgi complex is an important step for apoptosis. However, Obeid et al. showed that PKC activation by TPA inhibited ceramide-induced DNA fragmentation (47) and suggested the involvement of two signaling pathways, ceramide-and PKC-associated pathways, in the regulation of apoptosis. The present study showed that TPA evokes translocation of ␦PKC to the plasma membrane even after ceramide translocates ␦PKC to the Golgi complex, suggesting that the inhibitory effect of TPA on DNA fragmentation is due to the different targeting of PKC but not to the activation of PKC in the same intracellular compartment to which PKC was translocated by ceramide.
In conclusion, IFN-␥ stimulation followed by ceramide generation through Mg 2ϩ -dependent neutral sphingomyelinase induced ␦PKC-specific translocation to the Golgi complex, and this translocation resulted in ␦PKC activation through tyrosine phosphorylation of the enzyme.
